Concepedia

Author

Jorge Riera Knorrenschild

Philipps University of Marburg

Also Known As

J R Knorrenschild, J Riera Knorrenschild, J. Riera Knorrenschild, J.R. Knorrenschild, Jorge Riera Knorrenschild, Jorge Riera Knorrenschild, J Riera Knorrenschild, Knorrenschild, Jorge Riera, Stefanie Hayoz

66

Publications

1.2K

Citations

14

H-Index

32

Concepts

All Affiliations

Philipps University of MarburgCharité - Universitätsmedizin BerlinKlinikum rechts der IsarTechnical University of MunichUniversitätsklinikum Gießen und Marburg
JR

About

Jorge Riera Knorrenschild is an author at Philipps University of Marburg specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

306

2

Gastroenterology

3

3

154

3

Health Sciences

1

1

30

4

Public Health

1

1

171

5

Cellular Therapies

1

1

82

Jorge Riera Knorrenschild

×

18

Publications

1.1K

Citations

14

H-Index

YearCitations

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

Salah‐Eddin Al‐Batran, Thorsten Oliver Goetze, Daniel Mueller,

BMC Cancer

2017

218

Breaking bad news–what patients want and what they get: evaluating the SPIKES protocol in Germany

Carola Seifart, Mareike Hofmann, Tordis Bär,

Annals of Oncology

2014

171

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study

Ivonne Haffner, Katrin Schierle, Elba Raimúndez,

Journal of Clinical Oncology

2021

112

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)

Thomas Ruhstaller, Peter Thuss‐Patience, Stefanie Hayoz,

Annals of Oncology

2018

102

Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

Salah-Eddin Al-Batran, Sylvie Lorenzen, Peter Thuss‐Patience,

Journal of Clinical Oncology

2022

94

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

J C Albring, Sabrina Inselmann, Tim Sauer,

Bone Marrow Transplantation

2016

82

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag,

European Journal of Cancer

2015

60

Let us talk about death: gender effects in cancer patients’ preferences for end-of-life discussions

Carola Seifart, Jorge Riera Knorrenschild, Mareike Hofmann,

Supportive Care in Cancer

2020

55

Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: First results of a randomized phase III trial

M. Stahl, Martin K. Walz, Martin Stuschke,

Journal of Clinical Oncology

2007

30

1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK

S-E. Al-Batran, Sylvie Lorenzen, Nils Homann,

Annals of Oncology

2021

30

Page 1